Sahin et al. (2020) showed that 2 doses of BNT162b1 vaccine elicited robust CD4 + and CD8 + T cell responses and strong antibody responses, with RBD-binding IgG concentrations exceeding those observed in the serum of a group of people who recovered from COVID-19. Here, CD8A is linked to COVID-19.